CDER Pharmaceutical Quality Office Gains Permanent Director
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Novartis exec to join FDA in November.
You may also be interested in...
US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?
FDA reaches final stages of reorganization that will better distribute an ever-increasing review workload; recent high-level departures will make filling even more management slots difficult.
Inspection Delays Remain For Novel Approvals By US FDA; Will Quality Office Help?
Final assessment of the PDUFA V new drug review 'Program' flagged inspection delays as a continued sticking point for on-time approvals. US FDA says consolidation of manufacturing oversight under the agency’s new quality office will help.
CDER’s 50 Open Leadership Posts Could Be Bigger Hiring Challenges After Trump Freeze
President Trump’s hiring freeze on civilian employees will exacerbate the Center for Drugs Evaluation & Research’s existing difficulties in recruiting and retaining qualified individuals. CDER is currently 591 positions under the hiring ceiling, include 50 open positions within CDER management.